Gyre Therapeutics (GYRE) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Gyre Therapeutics Faces Revenue Decline Amidst Future Prospects
TipRanksFeb 18 06:33 ET
Insider Sale: President of $GYRE Sells 1,878 Shares
Quiver QuantitativeFeb 12 21:01 ET
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) Biggest Owners Are Public Companies Who Got Richer After Stock Soared 7.1% Last Week
Simply Wall StJan 29 06:56 ET
Leadership Changes at Gyre Therapeutics Amid Strategic Shift
TipRanksJan 6 07:28 ET
Express News | Gyre Therapeutics Inc - Ying Luo Resigns as Chairman of Gyre and Gyre Pharmaceuticals
ReutersJan 6 07:01 ET
Express News | Gyre Therapeutics Announces the Appointment of Ping Zhang to Board of Directors
ReutersJan 6 07:00 ET

Comments

108S

Jul 16, 2024 18:53

$Gyre Therapeutics (GYRE.US)$ sell or hold?

Jaguar8

May 30, 2024 15:11

NEWS

$Gyre Therapeutics (GYRE.US)$
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
Gyre Therapeutics (Nasdaq: GYRE), a biotech firm specializing in anti-fibrotic treatments, has received approval from China's NMPA for its Investigational New Drug (IND) application for F230. This drug, a selective endothelin receptor antagonist, is aimed at treating pulmonary arterial hypertension (PAH), a severe and progressive diso...

1

108S

May 29, 2024 08:33

$Gyre Therapeutics (GYRE.US)$Gyre Therapeutics Expects Addition To Russell - moomoo

Moomoo Recap US

Jan 22, 2024 15:13

Columns Wall Street Street | Great Day For Volume Stocks on Fresh Index Records

RECAP
U.S. stocks advanced on Monday, building off a record finish ahead of the ramping up of fourth-quarter earnings season.
The $Dow Jones Industrial Average (.DJI.US)$ rose 138 points, or 0.26%, to 38,000. The $S&P 500 Index (.SPX.US)$ was up 10 points, or 0.22%, at 4,850. The $Nasdaq Composite Index (.IXIC.US)$advanced 49 points, or 0.32%, to 15,360.
While the S&P 500 finally returned to record territory on Friday, skeptic...

29

3

7

Kevin Travers

Jan 22, 2024 09:51

Columns BiotTech Rises with the Index Tide

After two major indexes reached all-time highs, pharmaceutical stocks for companies in drug trials were caught up in the energy and rocketed forward. The largest gainers were $Spyre Therapeutics (SYRE.US)$, up 26% Monday morning, and $Gyre Therapeutics (GYRE.US)$ +10%.
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel. $Ginkgo Bioworks (DNA.US)$ also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not al...

4

1

GYRE Gyre Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks